GlassScriptPhysician profile
Evan G Kushner
NPI 1538108568
$2,037.57
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $202 · 2021: $29.18 · 2022: $625 · 2023: $647 · 2024: $19.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $298.67 | 2019-2023 | Evenity, Prolia |
| Abbvie INC. | $172.68 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $167.94 | 2019-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.79 | 2019-2023 | Trulance, Xifaxan |
| Amarin Pharma, INC. | $128.20 | 2019-2023 | |
| Abbott Laboratories | $125.91 | 2022-2024 | Freestyle Libre |
| Glaxosmithkline, LLC. | $108.52 | 2020-2023 | Shingrix, Arexvy |
| Novo Nordisk INC | $101.01 | 2022-2023 | Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $91.58 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $84.29 | 2022-2023 | Loreev Xr, Gralise |
| Pfizer INC. | $70.11 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $58.15 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $56.03 | 2023 | |
| Lilly USA, LLC | $47.80 | 2022-2023 | Mounjaro |
| Neurocrine Biosciences, INC. | $44.18 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $38.29 | 2019-2023 | Livalo, Seglentis |
| Allergan, INC. | $35.68 | 2020 | |
| Novartis Pharmaceuticals Corporation | $31.15 | 2019-2022 | |
| Therapeuticsmd, INC. | $29.92 | 2019 | |
| Medtronic, INC. | $26.33 | 2023 | Minimed 780g |
| Sanofi Pasteur INC. | $22.87 | 2019 | |
| Boston Scientific Corporation | $20.42 | 2019 | |
| Astellas Pharma US INC | $20.00 | 2023 | Myrbetriq |
| Seqirus USA INC | $17.00 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.52 | 2019 | |
| Hikma Pharmaceuticals USA | $13.66 | 2020 | |
| Ibsa Pharma INC. | $13.64 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.65 | 2022 | |
| Ucb, INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Kushner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.